SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Hassan Saadia)
 

Search: WFRF:(Hassan Saadia) > Evaluation of toxic...

Evaluation of toxicity and anti-tumour activity of cycloviolacin O2 in mice.

Burman, Robert, 1979- (author)
Uppsala universitet,Avdelningen för farmakognosi
Svedlund, Erika (author)
Uppsala universitet,Avdelningen för farmakognosi
Felth, Jenny, 1979- (author)
Uppsala universitet,Avdelningen för farmakognosi
show more...
Hassan, Saadia (author)
Uppsala universitet,Institutionen för medicinska vetenskaper
Herrmann, Anders, 1975- (author)
Uppsala universitet,Avdelningen för farmakognosi
Clark, Richard J. (author)
University of Queensland, Institute for Molecular Bioscience
Craik, David J. (author)
University of Queensland, Institute for Molecular Bioscience
Bohlin, Lars, 1948- (author)
Uppsala universitet,Avdelningen för farmakognosi
Claeson, Per (author)
Uppsala universitet,Avdelningen för farmakognosi
Göransson, Ulf, 1970- (author)
Uppsala universitet,Avdelningen för farmakognosi
Gullbo, Joachim (author)
Uppsala universitet,Institutionen för medicinska vetenskaper
show less...
 (creator_code:org_t)
2010-05-26
2010
English.
In: Biopolymers. - : Wiley. - 0006-3525 .- 1097-0282. ; 94:5, s. 626-634
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Cycloviolacin O2 is a small cyclic cysteine-rich protein belonging to the group of plant proteins called cyclotides. This cyclotide has been previously shown to exert cytotoxic activity against a variety of human tumor cell lines as well as primary cultures of human tumor cells in vitro. This study is the first evaluation of its tolerability and antitumor activity in vivo. Maximal-tolerated doses were estimated to 1.5 mg/kg for single intravenous (i.v.) dosing and 0.5 mg/kg for daily repeated dosing, respectively. Two different in vivo methods were used: the hollow fiber method with single dosing (i.v. 1.0 mg/kg) and traditional xenografts with repeated dosing over 2 weeks (i.v. 0.5 mg/kg daily, 5 days a week). The human tumor cell lines used displayed dose-dependent in vitro sensitivity (including growth in hollow fibers to confirm passage of cycloviolacin O2 through the polyvinylidene fluoride fibers), with IC50 values in the micromolar range. Despite this sensitivity in vitro, no significant antitumor effects were detected in vivo, neither with single dosing in the hollow fiber method nor with repeated dosing in xenografts. In summary, the results indicate that antitumor effects are minor or absent at tolerable (sublethal) doses, and cycloviolacin O2 has a very abrupt in vivo toxicity profile, with lethality after single injection at 2 mg/kg, but no signs of discomfort to the animals at 1.5 mg/kg. Repeated dosing of 1 mg/kg gave a local-inflammatory reaction at the site of injection after 2–3 days; lower doses were without complications.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Keyword

Cyclotides
toxicity
in vivo
xenograft
cycloviolacin O2
PHARMACY
FARMACI

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view